跳到主要內容區塊
Close
:::
Open
7/7/2025 3:41:38 PM
  1. Home_picHome
  2. > News

Events

:::
  • 20240202-1
  • Lectures
  • Institute of Biomedical Sciences
  • Location

    B1C Auditorium, IBMS

  • Speaker Name

    Dr. Jer-Yen Yang (China Medical Univ.)

  • State

    Definitive

  • Url
Exploiting Metabolic Vulnerability for Development of New Cancer Therapy

2024-02-02 11:00 - 12:00

Add To Calendar

Metabolic reprogramming is key for cancer development, yet the mechanism that sustains triple-negative breast cancer (TNBC) cell growth despite deficient pyruvate kinase M2 (PKM2) and tumor glycolysis remains to be determined. Here, we find that deficiency in tumor glycolysis activates a metabolic switch from glycolysis to fatty acid β-oxidation (FAO) to fuel TNBC growth. We show that, in TNBC cells, PKM2 directly interacts with histone methyltransferase EZH2 to coordinately mediate epigenetic silencing of a carnitine transporter, SLC16A9. Inhibition of PKM2 leads to impaired EZH2 recruitment to SLC16A9, and in turn de-represses SLC16A9 expression to increase intracellular carnitine influx, programming TNBC cells to an FAO-dependent and luminal-like cell state. Together, these findings reveal a new metabolic switch that drives TNBC from a metabolically heterogeneous-lineage plastic cell state to an FAO-dependent-lineage committed cell state, where dual targeting of EZH2 and FAO induces potent synthetic lethality in TNBC.

回頂端